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Background
We have developed a modified virus capture assay to dem-
onstrate the binding of multiple clades of HIV-1 to poly-
clonal and monoclonal anti-HIV-1 antibodies on protein
G coated plates. The results from the virus capture assay
were compared with the TZM-bl virus neutralization
assay.
Methods
Protein G plates were coated with 2F5, 4E10, 2G12, 21.2
(pooled positive HIV-1 human sera), or with anti-IgM
antibodies. Primary HIV-1 or pseudoviruses (pv) from
clades A [92UG(pv), 93RW(pv)], B [MN, US-1, MN(pv),
US-1(pv)], C [GS016], and D [57128(pv)], A07412(pv)]
were then added to the plates in the presence or absence
of sCD4 to determine the ability of the antibodies to cap-
ture virus. The amount of bound virus was determined by
a p24 ELISA. The appropriate viruses were also tested in a
TZM-bl neutralization assay using mAbs 2F5 and 4E10.
Results
Several viruses were captured by both 2F5 and 4E10
mAbs. However, the binding to 4E10 was much greater
than the binding to 2F5. US-1(pv) and GS016 were not
captured by either 4E10 or 2F5 antibodies and also were
not neutralized by the mAbs in the TZM-bl assay. In con-
trast, 4E10 did not neutralize 93RW(pv) even though it
captured the virus. Addition of sCD4 resulted in a signifi-
cant enhancement of binding of 93RW(pv), MN and
A3R5-US1 viruses suggesting that additional binding sites
on the viral surface were exposed. A decrease in virus cap-
ture was observed with the mAb 2F5 IgM isotype com-
pared to the IgG isotype.
Conclusion
The modified virus capture assay is highly versatile and is
currently being used to screen polyclonal and monoclonal
antibodies as well as MPER-specific multispecific IgM
mAbs that exhibit both protein and lipid binding.
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